Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.46 |
| ▸ | NMBR | P28336 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804088 | 1.00 | MEN1 (0.56) | MEN1RECQLKMT2ATACR3ITGB3 | |
| SCHEMBL22804099 | 1.00 | MEN1 (0.56) | MEN1RECQLKMT2ATACR3ITGB3 | |
| SCHEMBL22804071 | 0.94 | MEN1 (0.57) | MEN1RECQLKMT2ATACR3ITGB3 | |
| SCHEMBL22804073 | 0.94 | MEN1 (0.57) | MEN1RECQLKMT2ATACR3ITGB3 | |
| SCHEMBL17959465 | 0.90 | ADAM17 (0.53) | MEN1RECQLKMT2AITGB3ITGA2B | |
| SCHEMBL29400289 | 0.90 | ADAM17 (0.53) | MEN1RECQLKMT2AITGB3ITGA2B | |
| SCHEMBL17959463 | 0.90 | ADAM17 (0.53) | MEN1RECQLKMT2AITGB3ITGA2B | |
| SCHEMBL22804106 | 0.90 | ADAM17 (0.53) | MEN1RECQLKMT2AITGB3ITGA2B | |
| SCHEMBL29400895 | 0.90 | ADAM17 (0.53) | MEN1RECQLKMT2AITGB3ITGA2B | |
| SCHEMBL22804086 | 0.88 | MEN1 (0.49) | MEN1RECQLKMT2ATACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-3988538-B1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO LTD (CN) | 2024-08-07 | — | — | EP | disclosed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20220110909-A1 | PREPARATION METHOD AND USE OF MODIFIED HYDROPHOBIC EXCIPIENT | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20220111056-A1 | DRUG-LOADED EMULSION | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | MEN1 4516/4885RECQL 2777/4885KMT2A 855/4885 |
| US-20220111056-A1 | DRUG-LOADED EMULSION | SLC43A1, SLC7A1, CETP | MEN1 1927/4885RECQL 777/4885KMT2A 1926/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | MEN1 543/4885RECQL 3116/4885KMT2A 2845/4885 |
| US-20220110909-A1 | PREPARATION METHOD AND USE OF MODIFIED HYDROPHOBIC EXCIPIENT | ABCG2, CYP51A1, HACD3 | MEN1 3895/4885RECQL 2848/4885KMT2A 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.